TIME names NanoKnife one of 2025’s Best Inventions — already treating prostate cancer in Toronto with precise, function-preserving results. TIME's recognition of NanoKnife (IRE) reinforces what we’ve ...
Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment “The publication of the PRESERVE study in European ...
Function-Preserving Therapy Recognized in the Medical Devices Category for its Use of Irreversible Electroporation (IRE) Technology in Treatment of Prostate Tumors For the past 25 years, TIME’s Best ...
Zacks Investment Research on MSN
Reasons to add AngioDynamics stock to your portfolio for now
AngioDynamics ANGO has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optimism, led by a solid second-quarter fiscal 2026 performance, ...
At the recent American Urological Association (AUA) annual meeting, focal therapies for localized prostate cancer took center stage, moving from a niche option to a recognized alternative to surgery ...
PSA testing and digital rectal exams are crucial for early detection of prostate cancer, enabling timely intervention and improved outcomes. Treatment options include active surveillance, surgery, ...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results